ARTICLE | Clinical News

More RPC1063 data boosts Receptos

September 12, 2014 2:40 AM UTC

Investors have added $364 million in market cap to Receptos Inc. (NASDAQ:RCPT) over the past two days after the biotech provided the first look at annualized relapse rates (ARRs) for RPC1063 in multiple sclerosis, along with data that CEO Faheem Hasnain said show a "very benign" safety profile for the selective sphingosine-1-phosphate receptor 1 ( S1PR1; S1P1; EDG1) modulator.

In the Phase II portion of the Phase II/III RADIANCE study to treat relapsing multiple sclerosis, 1mg once-daily RPC1063 reduced ARR by 53%, while 0.5 mg reduced ARR by 31% vs. placebo. The study was not designed to detect differences in ARR between the treatment groups. ...